Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Therapy
3.3. Snippet by Cell Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Initiatives Taken by the Government and Private Organizations
4.1.1.2. The Growing Incidence of Acute Lymphocytic Leukemia
4.1.2. Restraints
4.1.2.1. Complications Associated with the Treatment
4.1.3. Opportunity
4.1.3.1. Rising Research and Development
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drugs
7.2.1. Pegasparaginase (Oncaspar) *
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2. Cyclophosphamide (Neosar)
7.2.3. Daunorubicin (Cerubidine)
7.2.4. Doxorubicin (Adriamycin)
7.2.5. Nelarabine (Arranon)
7.2.6. Rituximab (Rituxan)
7.2.7. Nilotinib (Tasigna)
7.2.8. Others
7.3. Surgery
7.4. Others
8. By Therapy
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.1.2. Market Attractiveness Index, By Therapy
8.2. Targeted Drugs & Immunotherapy *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiation Therapy
8.4. Chemotherapy
8.5. Stem Cell Transplantation
9. By Cell Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
9.1.2. Market Attractiveness Index, By Cell Type
9.2. Philadelphia Chromosome *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Precursor B-Cell ALL
9.4. T-Cell ALL
10. By End user
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.1.2. Market Attractiveness Index, By End User
10.2. Hospital & Hospital Pharmacy *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Radiation Therapy and Online Pharmacy
10.4. Ambulatory Surgical Centers
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
Australia
11.5.7.4. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Amgen Inc. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Bristol-Myers Squibb
13.3. Pfizer Inc.
13.4. Novartis AG
13.5. Sanofi
13.6. Takeda Pharmaceutical Company Limited
13.7. Spectrum Pharmaceuticals, Inc.
13.8. SymBio Pharmaceuticals Limited
13.9. Rare Disease Therapeutics, Inc.
13.10. Erytech Pharma
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us